中国中西医结合急救杂志2024年3月第26卷第2期Chin JTCMWM Crit Care, March 2024, Vol.26, No.2?227??论著?岩舒复方苦参注射液联合TP方案治疗晩期非小细胞肺癌的疗效观察
汤伟忠顾根网王国方丹阳市中医院肿瘤科，江苏镇江212300
通信作者：汤伟忠，Email : 93925667@qq.com【摘要】目的 观察岩舒复方苦参注射液联合紫杉醇+顺钳(TP)化疗方案治疗晚期非小细胞肺癌 (NSCLC)的临床疗效。方法 选择2014年5月至2024年6月丹阳市中医院肿瘤科收治的NSCLC患者 162例，所有病例均经病理学或细胞学确诊。将患者按给药种类的不同分为两组，每组81例。西药治疗组单 独采用TP方案治疗，3周为1个周期，连续治疗3个周期；中西医结合治疗组在西医TP化疗方案基础上同时 联用岩舒复方苦参注射液，连续治疗2周。观察两组治疗后临床疗效和不良反应发生率。结果 中西医结合 治疗组总有效率明显高于西药治疗组[60.49%(49/81)比40.74%(33/81), PV0.05〕；中西医结合治疗组脱发、 血小板减少、神经毒性、白细胞减少、恶心呕吐、胃肠反应等药物不良反应发生率较西药治疗对照组明显降低 〔脱发 24.69%(20/81)比 60.49%(49/81),血小板减少 23.45%(19/81)比 40.74%(33/81),神经毒性 14.81%( 12/81) 比 34.57% (28/81),白细胞减少 17.28% (14/81)比 62.96% (51/81),恶心呕吐 14.81% (12/81 ) tt 60.49% (49), 胃肠道反应27.16%(22/81)比62.96%(51/81),均PV0.05〕。结论 岩舒复方苦参注射液联合TP化疗方案 治疗晚期NSCLC的临床疗效显著,值得临床推广应用。【关键词】晚期非小细胞肺癌；岩舒复方苦参注射液；紫杉醇+顺钳化疗方案；中西医结合疗法DOI: 10.3969/j.issn. 1008-9691.2024.02.022Clinical observation on efficacy of Yanshu injection combined with paclitaxel and cisplatin regimen in treatment of advanced non-small cell lung cancer Tang Weizhong, Gu Genwang, Wang Guofang
Department of Oncology, Danyang Hospital of Traditional Chinese Medicine, Zhenjiang 212300, Jiangsu, China Corresponding author: Tang Weizhong, Email: 93925667@qq.com
[Abstract】 Objective To analyze the clinical efficacy of Yanshu compound sophora flavescens injection (Yanshu injection) combined with paclitaxel and cisplatin (TP) regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods One hundred and sixty-two patients with NSCLC admitted to the Department of Oncology of Danyang Hospital of Traditional Chinese Medicine from May 2014 to June 2024 were enrolled, all of their definite diagnosis was based on pathological or cytological examinations, and they were divided into two groups by the administration type, 81 cases in each group. The western medicine treatment group (western group) was treated with TP regimen alone, 3 weeks constituting 1 therapeutic course, and 3 consecutive courses were treated; based on the treatment of western drug TP regimen, the integrated traditional Chinese and western medicine treatment group (combined group) was additionally and simultaneously given Yanshu injection for consecutive 2 weeks. After treatment, the clinical efficacy and incidence of adverse reactions of the two groups were observed. Results The total effective rate in the combined group was significantly higher than that in western group [60.49% (49/81) vs. 40.74% (33/81), P < 0.05]; the incidences of adverse events: alopecia, thrombocytopenia, neurotoxicity, leukopenia, nausea and vomiting, and gastrointestinal reaction in the combined group were obviously lower than those in western group [alopecia: 24.69% (20/81) vs. 60.49% (49/81), thrombocytopenia: 23.45% (19/81) vs. 40.74% (33/81), neurotoxicity: 14.81% (12/81) vs. 34.57% (28/81), leukopenia: 17.28% (14/81) vs. 62.96% (51/81), nausea and vomiting: 14.81% (12/81) vs. 60.49% (49/81), gastrointestinal reaction: 27.16% (22/81) vs. 62.96% (51/81), all P < 0.05]. Conclusion Yanshu injection combined with TP regimen is obviously effective in the treatment of advanced NSCLC, thus it is worthy to be applied clinically.【Key words】 Advanced non-small cell lung cancer; Yanshu compound sophora flavescens injection; Paclitaxel and cisplatin regimen; Integrated traditional Chinese and western medicineDOI: 10.3969/j.issn. 1008-9691.2024.02.022临床上大概有3/4的肺癌患者入院诊疗时病情 用重组改构人肿瘤坏死因子(rmhTNF)联合常规化 疗治疗晚期非小细胞肺癌(NSCLC)有助于提高近 期临床疗效，改善患者的一般状况和生活质量⑷。
就已经发展到了中晚期，且5年生存率极低。肿瘤- 淋巴结-转移(TNM)分期在Mb期以后的肺癌便
可称为晚期肺癌，此时，癌症已经向骨髓、胸腔以及 身体其他部位扩散转移，根治手术已不适用Um,只 能采取以化疗为主的综合治疗方式来缓解各种临
近年来，随着临床研究的不断深入发现，中医药在 癌症病情控制上具有一定的应用价值⑸。王志光 等⑹采用中药健脾益肾补血法联合西药化疗治疗
床症状，控制病情,从而提高患者生活质量⑶。应
晚期NSCLC,结果显示中西医结合疗法能延长晚期
岩舒复方苦参注射液联合TP方案治疗晩期非小细胞肺癌的疗效观察 - 论文
